Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus albumin-bound paclitaxel for second-line advanced esophageal squamous cell carcinoma
ChiCTR2100045390Phase 2Recruiting
- Sponsor
- Anyang Cancer Hospital
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Anyang Cancer Hospital. Primary endpoint: Objective response rate. Started May 2021; status: recruiting.
02
Drugs
camrelizumabpaclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100045390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100045390.